SENZIME AB ORD (SNZZF) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 13 22 sessions, August 12, 2025 to September 2, 2026
- Largest daily move
- -22.4% close of November 24, 2025
- 1-year change
- -50.5% closing prices, August 12, 2025 to September 2, 2026
- 5-year change
- -86.6% closing prices, September 2, 2021 to September 2, 2026
Company Description
Senzime AB (SNZZF) develops and markets medical device systems for precision monitoring in anesthesia and perioperative care. The company’s flagship TetraGraph system monitors neuromuscular transmission during surgery, a clinical function used to guide dosing of neuromuscular blocking drugs and support recovery from anesthesia. Senzime is headquartered in Uppsala, Sweden, was established in 1999, is listed on the Nasdaq Stockholm Main Market under SEZI, and its ordinary shares cross-trade on the OTCQX Market as SNZZF.
The company’s product focus is centered on perioperative patient safety and operating-room monitoring. TetraGraph is used by anesthesia teams to generate objective neuromuscular data during surgical care. The system is marketed to hospitals and health systems, including integrated delivery networks in the United States, where centralized purchasing decisions can support system-wide adoption across affiliated facilities.
Senzime also offers TetraCom, a hospital connectivity platform designed to transmit real-time neuromuscular data from TetraGraph into electronic health record and clinical information systems. TetraCom combines a compact hardware gateway with a cloud-based software component and uses HL7 messaging to support interoperability with hospital enterprise systems such as Epic and Oracle Health systems. This extends the company’s role from device-based monitoring into anesthesia data integration for hospital information environments.
The company’s commercial model includes sales of monitoring systems to hospitals and healthcare networks, along with recurring revenue associated with installed systems. In the United States, Senzime’s commercial activity includes hospital contracts, integrated delivery network expansion, and access through group purchasing organization agreements. Its operating structure also includes sales, clinical, and medical-affairs functions that support hospital adoption, training, and use of the company’s monitoring technology.
Senzime operates within the medical device market for perioperative and anesthesia care. Its business is shaped by hospital procurement processes, operating-room clinical practice, and the broader shift toward quantitative monitoring and digital transmission of clinical data during surgery and recovery.
Stock Performance
SENZIME AB ORD (SNZZF) closed at $0.3491 on September 2, 2026. Over the past 12 months, the price has lost 50.5%.
SNZZF Metrics & Rankings
Price returns through September 2, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SENZIME AB ORD has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 1 with negative movement. Key topics include partnership. View all SNZZF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in SENZIME AB ORD (SNZZF) currently stands at 700 shares, representing 0.0% of the float. Since September 2025, short interest has decreased by 65.0%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for SENZIME AB ORD (SNZZF) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
SNZZF Company Profile & Sector Positioning
SENZIME AB ORD (SNZZF) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing SNZZF often look at related companies in the same sector, including QT IMAGING HOLDINGS (QTIH), RETINALGENIX TECHNOLOGIES (RTGN), CANNABIX TECHS INC ORD (BLOZF), POSITRON CORP (POSC), and ACARIX AB (ACIXF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SNZZF's relative position within its industry.